Recombinant Human CTLA-4 (CD152)

CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity.

The biological activity of Human CTLA-4 was determined by its ability to inhibit IL-2 production by Jurkat cells stimulated with Raji cells or 1 μg/ml rhB7-1/Fc in the presence of PHA (Linsley, P.S. et al., 1991, J. Exp. Med. 174:561). The expected ED₅₀ is typically 2 - 4 μg/ml with Raji cells or 0.1 - 0.4 μg/ml with rhB7-H1/Fc.

Fc Fusion Protein

amhv aqpavvlass rgiasfvcey aspgkatevr vtvlrqadsq vtevcaatym mgneltfldd sictgtssgn qvnltiqglr amdtglyick velmypppyy lgigngtqiy vidpepcpds dfiegrmdpk scdkthtcpp cpapellggp svflfppkpk dtlmisrtpe vtcvvvdvsh edpevkfnwy vdgvevhnak tkpreeqyns tyrvvsvltv lhqdwlngke ykckvsnkal papiektisk akgqprepqv ytlppsrdel tknqvsltcl vkgfypsdia vewesngqpe nnykttppvl dsdgsfflys kltvdksrwq qgnvfscsvm healhnhytq kslslspgkh hhhhh

Ala37

Lyophilized

The predicted molecular weight of Recombinant Human CTLA-4 is Mr 40 kDa.

40

This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Layrisse, Z. et al. (2009) Hum Immunol.70(7):532-5
2. Mak, TW. et al. (1995) Science 270: 985
3. Delneste, Y. et al. (1999) Eur. J. Immunol 29: 3596
4. Vijayakrishnan, L. et al. (2004) Immunity 20: 563